AlzChem Group (ACT) Company presentation summary

Company overview and market positioning

• International chemical company with a focus on high-quality, sustainable products and global development initiatives.

• Leading market positions in specialty chemicals, particularly in creatine, animal nutrition, plant growth regulators, and guanidine salts.

• Operates a fully integrated "Verbund" system, enabling flexibility and efficiency across specialty and basic chemicals.

• Strong barriers to entry through R&D, intellectual property, regulatory compliance, and established brands.

• Production sites in Germany and Sweden, with a global sales presence and a workforce of 1,765 employees.

Growth drivers and strategic investments

• Growth supported by megatrends: population growth, healthy aging, climate protection, safety, and sustainability.

• Major investments include €120 million in creatine capacity expansion and €140 million in nitroguanidine and guanidine nitrate facilities.

• Strategic partnership with Ehrmann brings creatine into the functional food segment, expanding market reach.

• US site selection underway for further capacity expansion, supported by grants from the EU and US Department of Defense.

• R&D focus on specialty chemicals, with approximately 70 patent families and ongoing innovation.

Financial performance and outlook

• Net sales for 2025 at €562 million, with EBITDA of €116.5 million and an EBITDA margin of 20%.

• Forecast for 2026 projects sales growth to approximately €600 million and EBITDA to €126 million.

• Specialty Chemicals segment drives growth, while Basics & Intermediates expected to remain stable.

• Equity ratio at 35%, net financial debt/EBITDA at -0.1x, and continued strong operating cash flow.

• Long-term vision targets €1 billion in sales with a 20% EBITDA margin through organic growth and M&A.